title: Hematopoietic stem cell therapy for malignant diseases.
abstract: Allogeneic bone marrow or blood stem cell transplantation (SCT) has changed its face in the last two decades. The introduction of nonmyeloablative conditioning regimens has reduced procedure toxicity and allowed the application of SCT in patients and conditions in which SCT was not offered in the past. In this review we will summarize the changes and accomplishments achieved in the past years in the field of stem cell transplantation for malignant disorders.
authors.affiliation: Department of Bone Marrow Transplantation & Cancer Immunotherapy, Hadassah University Hospital, Jerusalem 91120, Israel. shapiram@hadassah.org.il
authors.forename: Michael Y
authors.initials: MY
authors.lastname: Shapira
authors.forename: Ali Abdul
authors.initials: AA
authors.lastname: Hai
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Tsirigotis
authors.forename: Igor B
authors.initials: IB
authors.lastname: Resnick
authors.forename: Reuven
authors.initials: R
authors.lastname: Or
authors.forename: Shimon
authors.initials: S
authors.lastname: Slavin
mesh_terms: D006086:Graft vs Host Disease / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000639:trends*; D006801:Humans; D019172:Transplantation Conditioning / Q000379:methods